Hemospan: a hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia.
Hemospan, a novel hemoglobin-based oxygen carrier and plasma expander, is being developed by Sangart Inc for use as a blood substitute and for the treatment of critical limb ischemia. Hemospan is currently undergoing phase III clinical trials in Europe and phase II clinical trials in the US for use as a blood substitute, and phase II clinical trials in Sweden for critical limb ischemia.